Document is current
Any future updates will be listed below
-
Authors
Langelier, Marie-France
Billur, Ramya https://orcid.org/0000-0002-8677-0801
Sverzhinsky, Aleksandr https://orcid.org/0000-0003-1405-925X
Black, Ben E.
Pascal, John M. https://orcid.org/0000-0002-2714-4317
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35GM130302)
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (PJT173370)
- License Information
-
More Information
Article History
Received: 19 May 2021
Accepted: 29 October 2021
First Online: 18 November 2021
Competing interests
: B.E.B. and J.M.P. are co-founders of Hysplex, LLC with interests in PARP inhibitor development, B.E.B is on the scientific advisory board of Denovicon, and J.M.P. is a consultant for Xinthera. The remaining authors declare no competing interests.
